关键词: AAV ANCA C3 FSGS IgA nephropathy IgA vasculitis KDIGO MPGN anti-GBM complement evidence-based glomerular diseases glomerulonephritis guideline infection-related glomerulonephritis lupus nephritis membranous nephropathy minimal change disease nephrotic syndrome systematic review

Mesh : Adult Child Glomerulonephritis / diagnosis therapy Glomerulonephritis, IGA / diagnosis therapy Glomerulonephritis, Membranous / diagnosis drug therapy Humans Kidney Nephrosis, Lipoid

来  源:   DOI:10.1016/j.kint.2021.05.015

Abstract:
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the \"Grading of Recommendations Assessment, Development and Evaluation\" (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.
摘要:
肾脏疾病:改善全球结果(KDIGO)肾小球疾病管理临床实践指南是对KDIGO2012指南的更新。目的是帮助临床医生照顾肾小球肾炎(GN)患者,成人和儿童。范围包括各种肾小球疾病,包括IgA肾病和IgA血管炎,膜性肾病,肾病综合征,微小病变(MCD),局灶性节段肾小球硬化(FSGS),感染相关GN,抗中性粒细胞胞浆抗体(ANCA)血管炎,狼疮性肾炎,和抗肾小球基底膜抗体GN。此外,该指南将是第一个解决补体介导疾病亚型的指南.每章都遵循相同的格式,提供与诊断相关的指导,预后,治疗,和特殊情况。该指南的目标是通过基于证据综合提供可操作的建议,为临床医生和患者提供有用的资源,有用的信息图表结合了该领域专家的意见。另一个目的是为知识存在差距的领域提出研究建议。该指南针对治疗GN的临床医生的广泛全球受众,同时注意对政策和成本的影响。本指南更新的制定遵循了一个明确的过程,即治疗方法和指南建议基于相关研究的系统评价。并对证据质量和建议强度进行评估,开发和评估“(等级)方法。讨论了证据的局限性,还介绍了未来的研究领域。
公众号